Alfresa Holdings Corporation Stock

Equities

2784

JP3126340003

Medical Equipment, Supplies & Distribution

Delayed Japan Exchange 08:16:50 2024-07-03 pm EDT 5-day change 1st Jan Change
2,179 JPY -0.14% Intraday chart for Alfresa Holdings Corporation -1.22% -9.08%
Sales 2025 * 2,926B 18.1B Sales 2026 * 2,905B 17.97B Capitalization 408B 2.52B
Net income 2025 * 27.5B 170M Net income 2026 * 27.38B 169M EV / Sales 2025 * 0.14 x
Net cash position 2025 * - 0 Net cash position 2026 * - 0 EV / Sales 2026 * 0.14 x
P/E ratio 2025 *
14.7 x
P/E ratio 2026 *
14.7 x
Employees 12,517
Yield 2025 *
3.16%
Yield 2026 *
3.16%
Free-Float 84.72%
More Fundamentals * Assessed data
Dynamic Chart
Healios Enters Alliance, Bond Purchase Deal with Alfresa MT
Alfresa Holdings' Subsidiary Forms Pact with National Center for Child Health and Development to Supply Somatic Stem Cell Materials MT
Alfresa's Fiscal 2023 Attributable Profit Rises 15% on Net Sales Growth MT
Alfresa Holdings Corporation Revises Dividend Guidance for the Fiscal Year Ending March 31, 2024 CI
Alfresa Holdings Corporation Revises Consolidated Earnings Guidance for the Full Year Ending March 31, 2024 CI
Alfresa Holdings Corporation Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024 CI
Alfresa Holdings Corporation Provides Commemorative Dividend Guidance for the Fiscal Year Ending March 31, 2024 CI
Alfresa Holdings Corporation Provides Consolidated Earnings Guidance for the Full Year Ending March 31, 2024 CI
Alfresa Holdings Corporation Revises Consolidated Earnings Guidance for the First Half Ended September 30, 2023 and Fiscal Year March 31, 2024 CI
Alfresa Holdings Completes 35 Billion Yen Share Buyback program MT
Tranche Update on Alfresa Holdings Corporation's Equity Buyback Plan announced on May 15, 2023. CI
Tranche Update on Alfresa Holdings Corporation's Equity Buyback Plan announced on May 15, 2023. CI
Alfresa Holdings Corporation's Equity Buyback announced on May 15, 2023, has closed with 15,201,200 shares, representing 7.65% for ¥34,999.80 million. CI
Alfresa unit Cell Resources Partners with Miltenyi Biotec to Advance Cell Culture Automation in Gene Cell Therapy Market MT
Alfresa Holdings Corporation Provides Consolidated Earnings Guidance for the First Half and Full Year Ending March 31, 2024 CI
More news
1 day-0.14%
1 week-1.22%
Current month-1.09%
1 month-2.27%
3 months-1.11%
6 months-10.55%
Current year-9.08%
More quotes
1 week
2 171.50
Extreme 2171.5
2 236.00
1 month
2 069.50
Extreme 2069.5
2 236.00
Current year
2 069.50
Extreme 2069.5
2 554.50
1 year
2 069.50
Extreme 2069.5
2 643.50
3 years
1 505.00
Extreme 1505
2 643.50
5 years
1 505.00
Extreme 1505
2 807.00
10 years
1 281.00
Extreme 1281
3 350.00
More quotes
Managers TitleAgeSince
Director of Finance/CFO 64 18-03-31
President 61 07-05-31
Compliance Officer - -
Members of the board TitleAgeSince
Director/Board Member 48 20-05-31
President 61 07-05-31
Director/Board Member 70 20-05-31
More insiders
Date Price Change Volume
24-07-03 2,179 -0.14% 19 300
24-07-03 2,182 -1.47% 518,400
24-07-02 2,214 +0.70% 360,500
24-07-01 2,199 -0.18% 323,400
24-06-28 2,203 +0.30% 246,900

Delayed Quote Japan Exchange, July 03, 2024 at 08:16 pm EDT

More quotes
Alfresa Holdings Corporation is a Japan-based holding company primarily engaged in the wholesale of drugs. The Company operates in four business segments. The Pharmaceutical Wholesale segment is engaged in the wholesale of medical products, test reagents, as well as medical equipment and materials. The Self Medication Wholesale segment is engaged in the wholesale of general drugs. The Pharmaceutical Manufacture segment is engaged in the manufacture and sale of pharmaceuticals, test reagents, medical equipment and implements, as well as pharmaceutical powders. The Medical-Related segment is mainly engaged in operation of pharmacies. The others business is engaged in the information system business, the transportation business, the warehousing business, the insurance agency business, the real estate management business, the sale of miscellaneous goods, as well as the manpower dispatching business, among others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
4
Last Close Price
2,182 JPY
Average target price
2,240 JPY
Spread / Average Target
+2.66%
Consensus